Domestic developed drugs continued to be strong in the foreign prescription drug market. Hanmi Pharmaceutical's complex new drug Rosuzet exceeded 100 billion won in prescriptions in three quarters, while HK inno.N's new drug K-CAB booked 100 billion won for the second consecutive year.

According to UBIST, a drug research institute, on the 23rd, Viatris' hyperlipidemia drug Lipitor took the lead with a cumulative outpatient prescription amount of 147.7 billion won in the third quarter of this year. Although it decreased by 3.2% compared to the same period last year, it maintained a gap of more than 40 billion won with the second-ranked group and continued to take a relaxed lead. Lipitor was released in Kore